20 July 2021: Clinical Research
Risk Prediction Model Based on Biomarkers of Remodeling in Patients with Acute Anterior ST-Segment Elevation Myocardial Infarction
Zeyan Liu 12ABCDEF , Lijun Liu 1E* , Jinglin Cheng 2BCF , Hao Zhang 2FGDOI: 10.12659/MSM.927404
Med Sci Monit 2021; 27:e927404
Table 2 Laboratory indicators in the non-LVR and LVR groups, (χ̄±s) or M(Q25, Q75).
| Variables | Total | Non-LVR (n=198) | LVR (n=135) | t/Z | P |
|---|---|---|---|---|---|
| NLR,% | 6.56±4.69 | 5.77±4.23 | 7.72±5.08 | −3.67 | |
| PDW, fL | 16.08±1.72 | 15.85±1.87 | 16.42±1.41 | −3.17 | 0.002 |
| Platelet count, 10/L | 198.39±66.21 | 198.32±68.54 | 198.50±62.89 | −0.02 | 0.981 |
| Hemoglobin, g/L | 139.87±19.13 | 142.29±17.55 | 136.33±20.80 | 2.73 | 0.007 |
| WBC count, 10/L | 9.99±3.50 | 9.68±3.47 | 10.43±3.51 | −1.93 | 0.054 |
| Creatinine, μmol/L | 92.61±40.79 | 89.49±22.09 | 97.19±58.05 | −1.47 | 0.144 |
| UA, μmol/L | 333.94±99.94 | 330.12±93.73 | 339.55±108.51 | −0.85 | 0.399 |
| Hcy, mmol/L | 14.45±3.80 | 13.04±2.89 | 16.51±4.02 | −8.61 | |
| Glycosylated hemoglobin, % | 5.94±1.45 | 5.91±1.39 | 5.98±1.54 | −0.41 | 0.682 |
| cTnI, ng/mL | |||||
| At admission | 5.37 (1.14, 17.91) | 2.05 (0.62, 5.01) | 20.10 (11.02, 48.52) | 12.789 | |
| 3 d after admission | 17.23 (13.83, 29.94) | 16.26 (13.38, 21.33) | 22.67 (15.54, 41.16) | 4.479 | |
| rh-BNP, mg/L | 202.00 (98.00, 443.00) | 121.00 (67.00, 198.00) | 454.00 (277.00, 823.00) | 12.213 | |
| TGF-β, pg/mL | |||||
| At admission | 204.73±29.19 | 197.72±30.49 | 215.01±23.77 | −5.80 | |
| 24 h after admission | 301.12±60.02 | 257.08±26.12 | 365.73±29.16 | −35.54 | |
| 3 d after admission | 377.54±78.56 | 319.18±30.20 | 463.12±39.26 | −35.96 | |
| ALT, μ/L | 40.58±24.68 | 39.19±21.32 | 42.61±28.87 | −1.18 | 0.240 |
| AST, μ/L | 57.00 (27.00, 137.00) | 47.00 (26.00, 91.00) | 100.00 (33.00, 196.00) | 4.739 | |
| Total bilirubin, μmol/L | 12.53±6.56 | 11.95±6.00 | 13.39±7.24 | −1.91 | 0.057 |
| LDH, Mean±SD | 358.46±258.74 | 235.43±61.11 | 538.89±324.36 | −10.74 | |
| D-dimer, μg/mL | 0.29 (0.19, 0.56) | 0.25 (0.19, 0.47) | 0.36 (0.21, 0.79) | 2.930 | 0.003 |
| Fibrinogen, g/L | 2.98±1.01 | 2.95±0.88 | 3.03±1.17 | −0.68 | 0.497 |
| Myoglobin, ng/mL | 155.00 (123.60, 216.40) | 137.20 (109.20, 174.90) | 204.90 (146.60, 298.00) | 7.956 | |
| CK-MB, μ/L | 40.00 (27.00, 61.00) | 30.50 (25.00, 43.00) | 69.00 (44.00, 140.00) | 10.225 | |
| hs-CRP, mg/L | |||||
| At admission | 4.90 (2.50, 11.30) | 3.33 (1.51, 5.50) | 11.90 (7.30, 19.91) | 10.697 | |
| 3 d after admission | 6.90 (4.80, 14.40) | 6.10 (4.58, 9.65) | 11.30 (5.70, 16.50) | 5.071 | |
| Total cholesterol, mmol/L | 4.79±1.20 | 4.76±1.17 | 4.84±1.25 | −0.57 | 0.569 |
| HDL-C, mmol/L | 1.20±0.41 | 1.24±0.45 | 1.13±0.34 | 2.56 | 0.011 |
| LDL-C, mmol/L | 3.03±1.04 | 3.00±0.98 | 3.07±1.12 | −0.58 | 0.563 |
| Apolipoprotein a, g/L | 1.38±0.37 | 1.31±0.30 | 1.48±0.44 | −3.82 | |
| Apolipoprotein b, g/L | 1.23±0.52 | 1.25±0.42 | 1.19±0.63 | 0.92 | 0.359 |
| ALT – glutamic-pyruvic transaminase; AST – glutamic oxalacetic transaminase; LDH – lactic dehydrogenase; CK-MB – creatine kinase-myocardial band; cTnI – cardiac troponin I; Hcy – homocysteine; HDL-C – high-density lipoprotein cholesterol; hs-CRP – high-sensitivity C-reactive protein; LDL-C – low-density lipoprotein cholesterol; LVR – left ventricular remodeling; NLR – neutrophil/lymphocyte ratio; PDW – platelet distribution width; rh-BNP – recombinant human brain natriuretic peptide; TGF-β – transforming growth factor-beta; UA – uric acid; WBC – white blood cell. | |||||